SKI V - CAS:24418-86-8 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	SKI V
英文名称:	SKI V
CAS No:	24418-86-8	分子式:	C₁₅H₁₀O₄	分子量:	254.24
CAS No:	24418-86-8
分子式:	C₁₅H₁₀O₄
分子量:	254.24

点击下载产品说明书(PDF)

S10715 SKI V ≥98% (psaitong)

相关产品

包装规格：

1mg 5mg 10mg in glass bottle

溶解性：

溶于DMSO（250 mg/mL 超声）

产品描述：

基本信息

产品编号：	S10715
产品名称：	SKI V
CAS:	24418-86-8	储存条件	粉末	-20℃	四年

分子式：	C15H10O4		溶于液体	-80℃	6个月
分子量：	254.24			-20℃	1个月
化学名：	2-(3,4-Dihydroxy-benzylidene)-benzofuran-3-one,Sphingosine Kinase Inhibitor V
Solubility (25°C)：
体外:	DMSO	51mg/mL (200.59mM)
	Ethanol	Insoluble
	Water	Insoluble
体内(现配现用):
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	3.9333mL	19.6665mL	39.3329mL
5mM	0.7867mL	3.9333mL	7.8666mL
10mM	0.3933mL	1.9666mL	3.9333mL
50mM	0.0787mL	0.3933mL	0.7867mL

生物活性

产品描述	一种非竞争性的，有效的非脂质鞘氨醇激酶(SPHK;SK)抑制剂，对GST-hSK的IC50为2μM。
靶点	GST-hSK		hPI3k
	2μM		6μM
体外研究	SKI V has weak activity toward ERK2 (IC50 of 80μM for hERK2) and does not inhibit PKC-α.SKI V (10μM;for 24 hours) inhibits cancer cell proliferation and induces apoptosis.SKI V (0.2,1,5μM;pretreated for 1 hour) decreases phospho-Akt and phospho-MEK levels.Near-confluent cultures of JC cells are serum-starved for 16 hours,followed by pretreatment SKI V for 1 hour.SKI V has IC50s for inhibition of sphingosine kinase (SK) and tumor cell proliferation of -2μM.SKI V (20μg/ml) inhibits not only purified but endogenous SK in in MDA-MB-231 cells.SKI V (0.2,1,5μM) inhibits intracellular S1P formation in JC cells in a dose-dependent fashion. Cell Proliferation Assay
	Cell Line:	T24 tumor cells
	Concentration:	10μM
	Incubation Time:	For 24 hours
	Result:	Inhibited cancer cell proliferation.
	Apoptosis Analysis
	Cell Line:	T24 tumor cells
	Concentration:	10μM
	Incubation Time:	For 24 hours
	Result:	Induced apoptosis.
	Western Blot Analysis
	Cell Line:	JC cells
	Concentration:	0.2,1,5μM
	Incubation Time:	Pretreated for 1 hour
	Result:	Decreased phospho-Akt and phospho-MEK levels.
体内研究	SKI V (75mg/kg;i.p.;days 1,5,9,15) significantly lowers tumor growth (>50% decreased at day 18) than control animals.
	Animal Model:	6-8 weeks old BALB/c female mice with JC mammary adenocarcinoma cells
	Dosage:	75mg/kg
	Administration:	IP;days 1,5,9,15
	Result:	Tumor growth was significantly lower (>50% decreased at day 18) than tumor growth in control animals.